睿知中国医院研究地图
候选清单

正在招募乳腺癌I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由湖南省肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT05535413,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 70 岁;性别:仅女性

    登记记录的入选字段

  2. With histologically confirmed HER2 negative recurrent and metastatic breast cancer

    入选标准第 2 条

  3. All toxicities related to the previous anti-tumor treatment of patients who have not received chemotherapy, radiotherapy, surgical treatment, targeted therapy and immunotherapy within 4 weeks before enrollment must be restored to ≤ level 1 (CTCAE v50). However, patients with hair loss of any grade are allowed to be recruited.

    入选标准第 11 条

    Use capecitabine within 6 months before enrollment; No response to capecitabine in the past (including progression during capecitabine treatment, or duration of clinical response after treatment < 3 months) or unable to tolerate to capecitabine.

    排除标准第 6 条

  4. ECOG score (PS) of 0-2

    入选标准第 4 条

  5. White blood cell count (WBC) ≥ 30 × 109 /L

    入选标准第 13 条

    Neutrophil counts (ANC) ≥ 15 × 109/L

    入选标准第 14 条

    Platelet count (PLT) ≥ 100 × 109 /L

    入选标准第 15 条

    Hemoglobin ≥ 90g/dl. Patients can receive blood transfusion or erythropoietin treatment to meet this standard.

    入选标准第 16 条

    Total bilirubin ≤ 15 × Upper limit of normal value (ULN)

    入选标准第 18 条

    Alanine aminotransferase (SGPT / ALT) ≤ 25 x ULN (patients with liver metastasis ≤ 5 × ULN)

    入选标准第 19 条

    Glutamic oxaloacetic transaminase (SGOT/AST) ≤ 25 × ULN (patients with liver metastasis ≤ 5 × ULN)

    入选标准第 20 条

    Creatinine clearance rate (Ccr) ≥ 60ml/min patients

    入选标准第 21 条

  6. have at least one measurable lesion in the central nervous system (the longest diameter ≥ 10mm)

    入选标准第 3 条

  7. Other malignant carcinomas (including primary brain or leptomeningeal related tumors) in the past 5 years, except for the cured basal cell carcinoma of the skin and carcinoma in situ of the cervix.

    排除标准第 2 条

  8. With fertility must agree to use effective contraceptive methods during the study period and within 90 days of the last study medication. Before enrollment, the blood or urine pregnancy test must be negative and the

    入选标准第 22 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05535413,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Patients aged 18 to 70 years
  2. With histologically confirmed HER2 negative recurrent and metastatic breast cancer
  3. have at least one measurable lesion in the central nervous system (the longest diameter ≥ 10mm)
  4. ECOG score (PS) of 0-2
  5. According to screening brain MRI, patients with CNS must meet the following conditions:
  6. untreated brain metastases of breast cancer;
  7. do not need immediate local treatment;
  8. brain metastases of breast cancer which was treated in the past:
  9. There are no clinical manifestations that have progressed after the previous local treatment of the central nervous system and require immediate local treatment.
  10. All records related to the treatment of the central nervous system must be provided.
  11. All toxicities related to the previous anti-tumor treatment of patients who have not received chemotherapy, radiotherapy, surgical treatment, targeted therapy and immunotherapy within 4 weeks before enrollment must be restored to ≤ level 1 (CTCAE v50). However, patients with hair loss of any grade are allowed to be recruited.
  12. Blood routine examination was basically normal within 1 week before enrollment.
  13. White blood cell count (WBC) ≥ 30 × 109 /L
  14. Neutrophil counts (ANC) ≥ 15 × 109/L
  15. Platelet count (PLT) ≥ 100 × 109 /L
  16. Hemoglobin ≥ 90g/dl. Patients can receive blood transfusion or erythropoietin treatment to meet this standard.
  17. Within 1 week before enrollment, the liver and kidney function tests were basically normal (based on the normal value of the laboratory of each research center).
  18. Total bilirubin ≤ 15 × Upper limit of normal value (ULN)
  19. Alanine aminotransferase (SGPT / ALT) ≤ 25 x ULN (patients with liver metastasis ≤ 5 × ULN)
  20. Glutamic oxaloacetic transaminase (SGOT/AST) ≤ 25 × ULN (patients with liver metastasis ≤ 5 × ULN)
  21. Creatinine clearance rate (Ccr) ≥ 60ml/min patients
  22. With fertility must agree to use effective contraceptive methods during the study period and within 90 days of the last study medication. Before enrollment, the blood or urine pregnancy test must be negative and the
  23. Life expectancy > 12 weeks.
  24. The patient must be able to participate in and follow the treatment and follow-up.

排除标准:Exclusion Criteria:

  1. Primary or metastatic lesions were HER2 positive (HER2 IHC or FISH positive)
  2. Other malignant carcinomas (including primary brain or leptomeningeal related tumors) in the past 5 years, except for the cured basal cell carcinoma of the skin and carcinoma in situ of the cervix.
  3. Anti tumor treatment, including chemotherapeutic radical radiotherapy, hormone therapy, biological therapy Immunotherapy or anti-tumor traditional Chinese medicine.
  4. Patients who have received surgical operation on major organs (excluding puncture biopsy) or have suffered significant trauma within 4 weeks before the first use of the study drug, or who need to undergo elective surgery during the trial.
  5. Patients with symptomatic peripheral neuropathy with grade evaluation ≥ 2 (CTCAE 5.0), who have previously used anti-microtubule drugs and have serious adverse reactions related to the nervous system of grade 3 or above.
  6. Use capecitabine within 6 months before enrollment; No response to capecitabine in the past (including progression during capecitabine treatment, or duration of clinical response after treatment < 3 months) or unable to tolerate to capecitabine.
  7. For any brain lesions requiring immediate local treatment, such as increased lesion size or treatment-related edema at intracranial (but not limited to) anatomical sites may pose risks to patients (e.g., brainstem lesions)
  8. Known or suspected leptomeningeal disease (LMD)
  9. Other non malignant systemic diseases (cardiovascular, renal, liver, etc.) that are excluded from any treatment regimen or interfere with follow-up in pregnant or lactating women.
  10. Known or suspected allergy to any study drug or accessories.
  11. Brain MRI can not be performed for any other reason.
  12. The investigator considers it inappropriate to participate in.
  13. Other situations where corticosteroids are prohibited.

引自 ClinicalTrials.gov, NCT05535413, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05535413,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05535413